AIDS Drug Assistance Program ADAP-Miami. NEEDS ASSESSMENT July 16, 2010

Similar documents
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

Drug Treatment Program Update

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

Genotyping and Drug Resistance in Clinical Practice. Case Studies

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

HIV Drugs and the HIV Lifecycle

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases

Midwestern Underwriting Conference 2016

Division of Public Health Services Office of the Assistant Director Public Health Preparedness Services

Lesson 3: HIV Poverty

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

New York State Department of Health HIV Uninsured Care Programs

HIV and YOU. Special 2008 Update!

HIV medications HIV medication and schedule plan

Generic Name Brand Name Restrictions or Notes 1a. ANTIRETROVIRALS-ENTRY INHIBITORS (2) 1b. ANTIRETROVIRALS-INTEGRASE INHIBITOR(3)

May 2016 P & T Updates

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

Nothing to disclose.

AIDS DRUG ASSISTANCE PROGRAM (ADAP) FORMULARY - CLIENT VERSION

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

ANTIRETROVIRAL TREATMENTS (Part 1of


HIV Integrase Inhibitors: Current and Future Use. Douglas G. Fish, MD Albany Medical College Cali, Colombia March 13, 2008

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Recommended comparator products: Medicines for HIV/AIDS and related diseases

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Projeto Praça Onze Universidade Federal do Rio de Janeiro. Long term treatment of chronic viral disease: lessons from HIV for HBV

Human Immunodeficiency Virus Infection A Modern Day Epidemic

Medication Guide. October Contents. Preferred Medication List

Appropriate Use & Safety Edits

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

Generic Name Brand Name Restrictions or Notes 1a. ANTIRETROVIRALS-ENTRY INHIBITORS (1) 1b. ANTIRETROVIRALS-INTEGRASE INHIBITOR(2)

Antiretrovial Crushable/Liquid Formulation Chart

Antiretroviral Dosing in Renal Impairment

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

Section H: Treatments

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

Sculpting a Better Regimen: The ART of HIV Medications

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

Emblem Medicaid 4th Quarter Formulary Updates

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

HIV Infection & AIDS in Low- and Middle-Income Countries

Antiretroviral Pregnancy Registry

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010

NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters

treatment passport 1

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

Nobel /03/28. HIV virus and infected CD4+ T cells

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

HIV Clinical Nurse Specialist CCDHB Wellington

World AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary

Approach for the Newly Diagnosed HIV Positive Patient

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

30 Years of HIV: An Update on Treatment Guidelines and Beyond

Chapter 12. HIV Drug Glossary. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) *

HIV / AIDS & Opportunistic Infections.

P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS

Cystic Fibrosis Agents

Medication Guide. July Contents. Click to search for a drug name in this document

Cystic Fibrosis Agents

continuing education for pharmacists

State of Alabama AIDS Drug Assistance Program (ADAP) Quarterly Report

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

HIV Management Update 2015

Addressing Pediatric Needs of the Most Neglected: next steps

October 26-28: Training Day 1

Agents for Cystic Fibrosis

MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

New Frontiers for Treatment Strategies for HIV Care

Maraviroc (Celsentri)

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

HIV/AIDS Update 2007

HIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications

Gilead Sciences, LLC 50

ADR 2014 Data Validations

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Bristol-Myers Squibb and Gilead Sciences, LLC 50

2016 Prescription Drug Guide

PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY

Health Insurance Marketplace 6 Tier Drug List

Medication Guide. January Contents

Transcription:

AIDS Drug Assistance Program ADAP-Miami NEEDS ASSESSMENT July 16, 2010

ADAP Clients - Gender ADAP Clients by Gender FY 09/10 April 2010 to June 2010 26% 0% Males Females 26% 0% Males Females Transgender Transgender 74% 74% Note: Figures include eight (8) transgendered clients Source: Bureau of HIV/AIDS 7/13/2010

ADAP Clients - AGE ADAP Clients by Fiscal Yr 09/10 60% 40% 44% 51% 20% 0% 0% 0% 3% Lessthan2years 2 12years 13 24years 25 44years 45 64years 65yearsorolder 2% ADAP Clients by Age - April 2010 - June 2010 60% 40% 45% 50% 20% 0% 0% 0% 3% Lessthan2years 2 12years 13 24years 25 44years 45 64years 65yearsorolder 2% Source: Bureau of HIV/AIDS 7/13/2010

ADAP Clients - Ethnicity ADAP Clients by Ethnicity - Fiscal Yr 09/10 60% 50% 40% 30% 20% 10% 0% 52% 27% 8% 12% 0% 0% 0% 0% 0% 0% Nativ... Asian Pacifici... Black/A... Whitecaucas Multipl... Other Unknown Hispanic Haitian ADAP Clients by Ethnicity - April 2010 - June 2010 60% 50% 40% 30% 20% 10% 0% 0% 0% 0% 26% 8% 1% 0% 0% 53% 12% Nativeame... Asian Pacificisl... Black/Afri... Whitecauc... Multipleraces Other Unknown Hispanic Haitian Source: Bureau of HIV/AIDS 7/13/2010

ADAP Miami Current Clients as of 07/14/10 Current Open Cases = 3292 Wait List = 143 Source: ADAP database 7/14/2010

Requirements & Qualifications STEP 1 STEP 2 DOH PATIENT CARE CORE ELIGIBILITY HIV positive (+) test DOH ADAP PROGRAM QUALIFICATIONS HIV positive (+) test Florida residency Notice of Eligibility 400% FPL Household Income RX for ADAP meds Pt cooperation & truthfulness CD4 & VL ( 6 mo) NO other access to meds NO other access to meds

CORE ELIGIBILITY & ADAP QUALIFICATIONS APPLICATION PACKAGE 1. DOH CORE ELIGIBILITY Application form (2 pages/ patient responsibility) 2. DOH Consent to Fax (IF faxing to ADAP-Miami)) SUPPORTING DOCUMENTATION 1. Proof of HIV infection 2. Proof of Florida Residency 3. Proof of Household Income < 400 % FPL - (Paystub, bank statements, income tax, support letter, other, as needed) 4. Proof of NO other access to meds -(Programs, institutions, insurance, others, if needed) 5. Original Prescriptions / ADAP formulary / 6. CD4 & VL < 6 months ELIGIBILITY DETERMINATION & PROGRAM REGISTRATION NOTICE OF ELIGIBILITY ( official date of eligibility determination) AND ADAP REGISTRATION (official date of program enrollment)

PAPERWORK BY ADAP TRANSACTIONS TRANSACTION REQUIRED FORMS SUPPPORTING DOCUMENTS First ENROLLMENT CORE ELIGIBILITY APPLICATION FORM DOH 2116 CONSENT TO FAX (IF faxing) Medical Category Form if patient is enrolled on wait list * Proof of Florida Residency Proof of Household Income < 400 % FPL Proof of NO other access to meds Rx s CD4 & VL < 6 months old Re-Enrollment (six months) Drug Updates * DOH 2116 CONSENT TO FAX (IF faxing) * Proof of Florida Residency Proof of Household Income < 400 % FPL Proof of NO other access to meds Rx s CD4 & VL < 6 months old *Rx s REQUIRED DOH FORMS The ADAP program staff in Miami will prepare all the forms required by the Florida Department of Health that need to be signed by the applicant.

ADAP-Miami & ADAP-Florida Funding By FY FY Miami Florida % of FL 04/05 $ 30 702,077 $ 93 953,359 32.68 % 05/06 $ 32 124,491 $ 99 085,439 32.42 % (+$1 422,414) (+5 132,080) 06/07 $ 32 318,462 $101 385,439 31.87 % (+$ 194,071) (+$2 300,000) 07/08 $ 31 155,078 $106 282,478 29.31 % (-$1 163,384) (+4 901,039) 08/09 $ 25 042,762 $106 286,476 23.56 % (-$6 112,316) (+$3,998) 09/10 $ 19 572,047.61 $100 719,112.69 19.43 % (-$2 0829,70.93) (-$5 567,363.31) 10/11 $ 17,489,076.68 $ 85,188,435.00 20.53 %

ADAP Cost Containment Measures Cessation of RAMP (Beginning April 27, 2010) Suspension of Hepatitis C Program (Clients who are currently receiving Hepatitis C treatment through ADAP will be allowed to continue their current treatment) Reduction of Formulary (beginning August 1, 2010) Implemented Waiting List (beginning June 1, 2010)

New ADAP Formulary (On August 1, 2010 the listed medications will be available to ADAP clients) Beginning June 1, 2010, all new applicants (not reenrollments) must have a prescription for at least one (1) Antiretroviral (ARV) medication on the ADAP formulary to enroll in the program All ARVs + (APTIVUS, ATRIPLA, COMBIVIR, CRIXIVAN, EMTRIVA, EPIVIR, EPZICOM, FUZEON, INTELENCE, INVIRASE, ISENTRESS, KALETRA, LEXIVA, MARAVIROC, NORVIR, PREZISTA, RESCRIPTOR, RETROVIR, REYATAZ, SUSTIVA, TRIZIVIR, TRUVADA, VIDEX, VIRACEPT, VIRAMUNE, VIREAD, ZERIT, ZIAGEN) OPPORTUNISTIC INFECTION (OI s) BACTRIM DS (TMP/SMZ DS) BIAXIN (Clarithromycin) DARAPRIM (Pyrimethamine) DAPSONE (Diamino-diphenyl Sulfone) DIFLUCAN (Fluconazole) LEUCOVORIN (Folinic Acid) MEPRON (Atovaquone) MONISTAT (Miconazole) MYAMBUTOL (Ethambutol) MYCELEX TROCHE (Clotrimazole) MYCOBUTIN (Rifabutin) NIZORAL (Ketoconazole) SPORANOX (Itraconazole) SULFADIAZINE TERAZOL (Terconazole) VALCYTE (Valganciclovir Hcl) VALTREX (Valacyclovir) ZITHROMAX (Azithromycin) ZOVIRAX (Acyclovir

ADAP Wait List (implemented 6/1/2010) 143 clients from Miami-Dade as of July 14, 2010. Wail List is managed by the ADAP database All new clients and clients returning after a break in services are wait listed. Regular enrollment process is followed with one additional form (Medical Category Form) completed by provider. At time of Wait List enrollment, Client is given Notice of Eligibility letter and Wait List Notification. These may be used to apply for assistance from other programs. Medical Exceptions may be requested by the primary provider. Clients who have not picked up their medications and whose record is closed by and ADAP staff or by the program s automatic closure feature will have to reapply and will be considered new applicants. As funding becomes available, clients with the highest priority category on the waiting list will be enrolled in the ADAP. Source: ADAP Cost Containment Guidance

Wait List Categories Category A: Diagnosis of AIDS and /or CD4 <200 cells/mm3. Diagnosis of active opportunistic infection Diagnosis of HIV-associated nephropathy (HIVAN)

Wait List Categories Category B Persons who are currently on ARV therapy Persons who were previously on ARV therapy but therapy was interrupted Treatment naïve clients with CD4 cell count between 201-350 cells/mm3 Category C Treatment naïve clients with CD4 cell count >351 cells/mm3

Wait List Exceptions 1. Pregnant women who meet all other ADAP enrollment criteria and are not eligible for other programs. 2. Pediatric or adolescent persons who meet all other ADAP enrollment criteria and are not eligible for other programs. 3. Post partum women (gave birth within 180 days of application) needing to continue ARV medication with medical staff approval (requires Medical Exception Form) 4. Other extreme medical conditions with medical staff approval (requires medical Exception Form) The client s provider must complete and sign the Medical Exception Request Form. When ADAP staff receive the form, it is entered in the ADAP database. If exception is approved by Program Staff, the client is enrolled in the usual manner.

Wait List Forms filled out by Provider Medical Category Form Request for Medical Exception Used only when needed

Wait List Process Client brings application with Medical Category form to ADAP office.* Eligibility determined. Client entered onto statewide wait list. ADAP staff provide client with Notice of Eligibility and Wait List Notification letters. Local ADAP staff notified when there is opening for client Client is notified within 7 days that there is an opening Client information updated if needed and client is enrolled. If there is no response from the client, the enrollment will be made available to the next client on the wait list. If client does not have a Medical Category Form one will be provided by ADAP staff at time of Wait List entry, to be filled out and signed by provider and returned to ADAP office by client. (source: ADAP Cost Containment Guidance manual)